Patients suffering from chronic radiation-induced cystitis may find lasting relief through hyperbaric oxygen therapy, according to a five-year follow-up study from the RICH-ART trial. This research highlights the sustained benefits of HBO2 in improving urinary symptoms associated with pelvic cancer treatments.
Comprehensive Study Across Nordic Hospitals
Conducted at five reputable Nordic medical centers, the RICH-ART trial encompassed 223 screened individuals, with 87 participants ultimately enrolled. The study focused on adults aged between 18 and 80 who had undergone pelvic radiotherapy and were experiencing significant urinary distress. Participants were randomly assigned to either receive HBO2 therapy or continue with standard care, with the former group undergoing 30-40 sessions of 100% oxygen treatment under high pressure. The primary measure of success was the change in the Expanded Prostate Cancer Index Composite (EPIC) urinary score over five years.
Significant Improvement Sustained Over Years
Results revealed that patients receiving HBO2 exhibited a notable improvement in their EPIC urinary scores, with an average increase of 18 points at six months, which further stabilized to a 19-point improvement at the five-year mark. Approximately 69% of the participants experienced significant symptom relief, maintaining an average score increase of 22.9 points over the study period. Conversely, non-responders showed negligible improvement, and a small percentage required additional HBO2 treatments for recurring issues.
• HBO2 therapy led to a sustained improvement in urinary symptoms over five years.
• A significant majority of patients maintained their symptom relief long-term.
• Non-responders did not benefit from HBO2, indicating the need for patient selection criteria.
• Some patients required additional HBO2 sessions, suggesting variability in treatment efficacy.
The enduring positive effects observed in the study underscore HBO2’s potential as a reliable treatment option for those afflicted with chronic radiation-induced cystitis. By providing long-term symptom management, HBO2 can significantly enhance the quality of life for cancer survivors dealing with debilitating urinary issues.
Further research should aim to refine HBO2 treatment protocols, identify which patients are most likely to benefit, and assess the economic implications of widespread HBO2 use. Understanding these factors will be crucial in integrating HBO2 therapy into standard care practices effectively.
Healthcare providers should consider HBO2 as a viable option for managing chronic radiation-induced cystitis, especially for patients who have not found relief through conventional treatments. Continued advancements and studies in this area will likely improve patient outcomes and provide a more comprehensive approach to managing the long-term effects of pelvic radiotherapy.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
